Invesco Ltd. - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$266,245
-52.9%
125,587
+5.7%
0.00%
Q2 2023$565,469
-19.5%
118,796
-3.6%
0.00%
Q1 2023$702,588
+46.7%
123,261
+159.6%
0.00%
Q4 2022$479,063
-58.2%
47,479
-7.2%
0.00%
Q3 2022$1,146,000
-2.8%
51,166
+7.6%
0.00%
Q2 2022$1,179,000
-97.0%
47,550
-95.3%
0.00%
-100.0%
Q1 2022$39,356,000
-23.8%
1,015,117
+14.9%
0.01%
-16.7%
Q4 2021$51,680,000
+623.9%
883,279
+633.3%
0.01%
+500.0%
Q3 2021$7,139,000
-90.7%
120,447
-86.4%
0.00%
-89.5%
Q2 2021$76,734,000
+37.4%
884,134
+30.6%
0.02%
+26.7%
Q1 2021$55,831,000
+44.9%
677,136
+59.8%
0.02%
+36.4%
Q4 2020$38,541,000
+199.9%
423,856
+31.8%
0.01%
+175.0%
Q3 2020$12,853,000
+1412.1%
321,547
+1197.9%
0.00%
Q2 2020$850,000
-74.0%
24,774
-83.2%
0.00%
-100.0%
Q1 2020$3,275,000
+222.0%
147,462
+194.3%
0.00%
Q2 2019$1,017,000
+8.9%
50,107
-5.8%
0.00%
Q1 2019$934,000
+2.8%
53,179
-25.0%
0.00%
Q4 2018$909,000
-90.5%
70,862
-87.9%
0.00%
-100.0%
Q3 2018$9,559,000
+362.5%
586,778
+222.0%
0.00%
+200.0%
Q2 2018$2,067,000
+2985.1%
182,236
+778.8%
0.00%
Q2 2017$67,000
+17.5%
20,736
+66.4%
0.00%
Q1 2017$57,00012,4650.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$131,006,00024.77%
Redmile Group, LLC 12,957,222$502,351,00015.68%
Grosvenor Holdings, L.L.C. 1,037,256$40,214,0007.85%
Casdin Capital, LLC 3,400,000$131,818,0005.91%
Ally Bridge Group (NY) LLC 181,500$7,037,0005.22%
DAFNA Capital Management LLC 500,930$19,421,0005.06%
Deep Track Capital, LP 2,000,000$77,540,0004.97%
Artal Group S.A. 2,000,000$77,540,0003.25%
Tri Locum Partners LP 190,345$7,380,0002.88%
ARK Investment Management 10,988,182$426,012,0001.78%
View complete list of FATE THERAPEUTICS INC shareholders